SK Bioscience

Mergers and acquisitions usually happen in major global biopharma markets as a way to gain new technologies, R&D or commercial portfolios, expand a business or to beef up supply networks. But in S

The fourth quarter marked a continuation of weak earnings for many major South Korean pharma firms, hurt by factors including the continued impact of a long-running doctors’ protest against medical r

Major South Korean pharma firms have reported mixed earnings for the third quarter ended 30 September, with Yuhan logging strong earnings after the US approval of its novel lung cancer drug and Hanmi

Amid rising global cases of COVID-19 and mpox, the South Korean government has vowed to contribute an additional $18m to the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen the gl